MICA Risk Team Consultants are helping an increasing number of MICA members evaluate the medical professional liability risks of prescribing compounded semaglutide for weight loss
During a telehealth visit, be prepared to describe the lumps history (when it first appeared, changes in size, any associated symptoms), recent illnesses, vaccinations, animal exposures, and relevant medical history such as prior cancers or immunosuppression
Suitable for Vegetarians
Comparing Outcomes Studies show both GLP-1 medications and Wegovy support gradual, sustainable weight loss
Key findings from the research include: A significant association between GLP-1 medication use and increased risk of gastroparesis A 3.67-fold increase in the risk of developing gastroparesis among GLP-1 medication users An incidence rate of 0.53% among users of these medications These findings highlight the need for healthcare providers and patients to be aware of GLP-1 medication risks
The players who are underweight in patents relative to their disclosed pipeline are the ones most likely to be outside-licensing in the next twenty-four months
